BACKGROUND: Giant cell tumor of bone (GCTB) is a rare primary bone tumor, characterized by osteoclast-like giant cells that express receptor activator of nuclear factor-kappa B (RANK), and stromal cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. A RANKL-specific inhibitor, denosumab, was predicted to reduce osteolysis and control disease progression in patients with GCTB. PATIENTS AND METHODS: Seventeen patients with GCTB were enrolled. Patients were treated with denosumab at 120 mg every 4 weeks, with a loading dose of 120 mg on days 8 and 15. To evaluate efficacy, objective tumor response was evaluated prospectively by an independent imaging facility on the basis of prespecified criteria. RESULTS:...
BACKGROUND: In all giant-cell-rich lesions (GCRL) occurring in bone, a common underlying excessive R...
Giant cell tumor (GCT) of the bone also known as osteoclastoma typically arises from the meta-epiphy...
Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, i...
International audiencePURPOSE: Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteo...
AbstractObjectiveGiant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. ...
PubMedID: 28547968Giant cell tumor (GCT) is a rare, usually benign but locally aggressive neoplasm. ...
Purpose of review Giant cell tumor of bone (GCTB) is an uncommon benign primary bone tumor, consisti...
Background: Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal ...
Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surger...
Background: Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely metastazing...
Abstract Background Denosumab has been shown to reduce tumor size and progression, reform mineralize...
Background. Giant cell tumor of bone (GCTB) is an aggressive primary osteolytic tumor. GCTB often in...
BACKGROUND: Giant cell tumour of bone (GCTOB) is a relatively uncommon, benign, but locally aggressi...
Background: Giant cell tumour of bone (GCTB) is a very rare, aggressive, and progressive osteolytic ...
BACKGROUND: In all giant-cell-rich lesions (GCRL) occurring in bone, a common underlying excessive R...
BACKGROUND: In all giant-cell-rich lesions (GCRL) occurring in bone, a common underlying excessive R...
Giant cell tumor (GCT) of the bone also known as osteoclastoma typically arises from the meta-epiphy...
Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, i...
International audiencePURPOSE: Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteo...
AbstractObjectiveGiant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. ...
PubMedID: 28547968Giant cell tumor (GCT) is a rare, usually benign but locally aggressive neoplasm. ...
Purpose of review Giant cell tumor of bone (GCTB) is an uncommon benign primary bone tumor, consisti...
Background: Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal ...
Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surger...
Background: Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely metastazing...
Abstract Background Denosumab has been shown to reduce tumor size and progression, reform mineralize...
Background. Giant cell tumor of bone (GCTB) is an aggressive primary osteolytic tumor. GCTB often in...
BACKGROUND: Giant cell tumour of bone (GCTOB) is a relatively uncommon, benign, but locally aggressi...
Background: Giant cell tumour of bone (GCTB) is a very rare, aggressive, and progressive osteolytic ...
BACKGROUND: In all giant-cell-rich lesions (GCRL) occurring in bone, a common underlying excessive R...
BACKGROUND: In all giant-cell-rich lesions (GCRL) occurring in bone, a common underlying excessive R...
Giant cell tumor (GCT) of the bone also known as osteoclastoma typically arises from the meta-epiphy...
Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, i...